433 related articles for article (PubMed ID: 36705564)
1. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
Elife; 2023 Jan; 12():. PubMed ID: 36705564
[TBL] [Abstract][Full Text] [Related]
2. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T-cell-derived interleukin-15 shapes cytotoxic T cell memory.
Geginat J; Granucci F
Eur J Immunol; 2023 Jan; 53(1):e2250238. PubMed ID: 36398486
[TBL] [Abstract][Full Text] [Related]
4. Stem cell-derived tissue-associated regulatory T cells suppress the activity of pathogenic cells in autoimmune diabetes.
Haque M; Lei F; Xiong X; Das JK; Ren X; Fang D; Salek-Ardakani S; Yang JM; Song J
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30777937
[TBL] [Abstract][Full Text] [Related]
5. Suppression of allograft rejection by CD8+CD122+PD-1+ Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis.
Liu H; Wang Y; Zeng Q; Zeng YQ; Liang CL; Qiu F; Nie H; Dai Z
Oncotarget; 2017 Apr; 8(15):24187-24195. PubMed ID: 28445940
[TBL] [Abstract][Full Text] [Related]
6. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes.
Stocks BT; Wilson CS; Marshall AF; Hoopes EM; Moore DJ
J Immunol; 2019 Jul; 203(1):158-166. PubMed ID: 31127035
[TBL] [Abstract][Full Text] [Related]
8. Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy.
Zhou JY; Alvarez CA; Cobb BA
Elife; 2021 Feb; 10():. PubMed ID: 33617447
[TBL] [Abstract][Full Text] [Related]
9. Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.
Jaberi-Douraki M; Pietropaolo M; Khadra A
J Theor Biol; 2015 Oct; 383():93-105. PubMed ID: 26271890
[TBL] [Abstract][Full Text] [Related]
10. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
11. A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Ptacin JL; Ma L; Caffaro CE; Acuff NV; Germar K; Severy P; Qu Y; Vela JL; Cai X; San Jose KM; Aerni HR; Chen DB; Esche E; Ismaili TK; Herman R; Pavlova Y; Pena MJ; Nguyen J; Koriazova LK; Shawver LK; Joseph IB; Mooney J; Peakman M; Milla ME
Commun Med (Lond); 2024 Mar; 4(1):58. PubMed ID: 38532017
[TBL] [Abstract][Full Text] [Related]
12. How GRAIL controls Treg function to maintain self-tolerance.
Fathman CG; Yip L; Gómez-Martín D; Yu M; Seroogy CM; Hurt CR; Lin JT; Jenks JA; Nadeau KC; Soares L
Front Immunol; 2022; 13():1046631. PubMed ID: 36569931
[TBL] [Abstract][Full Text] [Related]
13. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity.
Tran GT; Hodgkinson SJ; Carter NM; Verma ND; Plain KM; Boyd R; Robinson CM; Nomura M; Killingsworth M; Hall BM
Blood; 2012 May; 119(19):4441-50. PubMed ID: 22310911
[TBL] [Abstract][Full Text] [Related]
14. IL-2-driven CD8
Niederlova V; Tsyklauri O; Kovar M; Stepanek O
Trends Immunol; 2023 Nov; 44(11):890-901. PubMed ID: 37827864
[TBL] [Abstract][Full Text] [Related]
15. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
17. Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice.
Vazquez-Mateo C; Collins J; Fleury M; Dooms H
BMC Immunol; 2017 Mar; 18(1):18. PubMed ID: 28356069
[TBL] [Abstract][Full Text] [Related]
18. Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells.
Huang W; Kachapati K; Adams D; Wu Y; Leung PS; Yang GX; Zhang W; Ansari AA; Flavell RA; Gershwin ME; Ridgway WM
J Autoimmun; 2014 May; 50():123-34. PubMed ID: 24556277
[TBL] [Abstract][Full Text] [Related]
19. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.
Bézie S; Charreau B; Vimond N; Lasselin J; Gérard N; Nerrière-Daguin V; Bellier-Waast F; Duteille F; Anegon I; Guillonneau C
Blood Adv; 2019 Nov; 3(22):3522-3538. PubMed ID: 31730699
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.
Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A
Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
